Molecule Details
| InChIKey | RYCBSFIKWACFBY-UHFFFAOYSA-N |
|---|---|
| Compound Name | 6-(2-chloro-4-(6-methylpyrazin-2-yl)phenyl)-8-ethyl-2-((2-(1-methylpiperidin-4-yl)ethyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one |
| Canonical SMILES | CCn1c(=O)c(-c2ccc(-c3cncc(C)n3)cc2Cl)cc2cnc(NCCC3CCN(C)CC3)nc21 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 3 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.53 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB31834 |
|---|---|
| Drug Name | FRAX1036 |
| CAS Number | 1432908-05-8 |
| Groups | experimental |
| ATC Codes | nan |
| Description | FRAX1036 is a p21-activated kinase (PAK) inhibitor. |
Cross-references: BindingDB: 50148931 CHEMBL3770186 PDB: 59U ZINC: ZINC000205502630